Prognostic evaluation of epidermal fatty acid-binding protein and calcyphosine, two proteins implicated in endometrial cancer using a proteomic approach

International Journal of Cancer

Volumn 123, Issue 10, 2008, Pages 2377-2383

  Li, Zhengyu ^a,b   Huang, Canhua ^b   Bai, Shujun ^b   Pan, Xiaoling ^a   Zhou, Rong ^a   Wei, Yuquan ^b   Zhao, Xia ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

CAPS; E FABP; Endometrial cancer; Prognostic factor; Survival analysis

Indexed keywords

BIOLOGICAL MARKER; CALCIUM BINDING PROTEIN; CALCYPHOSINE; EPIDERMAL FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN; UNCLASSIFIED DRUG; CAPS PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; ENDOMETRIAL INTRAEPITHELIAL NEOPLASIA; ENDOMETRIUM; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TISSUE; TISSUE DIFFERENTIATION; VALIDATION PROCESS; EPIDERMIS; METABOLISM;

CALCIUM-BINDING PROTEINS; EPIDERMIS; FATTY ACID-BINDING PROTEINS; HUMANS; PROGNOSIS; PROTEOMICS;

EID: 53449101474     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23808     Document Type: Article

References (26)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. Aglund K, Rauvala M, Puistola U, Angstrom T, Turpeenniemi-Hujanen T, Zackrisson B, Stendahl U. Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage. Gynecol Oncol 2004;94:699-704.
3. Markman M. Hormonal therapy of endometrial cancer. Eur J Cancer 2005;41:673-5.
4. Tu Z, Gui L, Wang J, Li X, Sun P, Wei L. Tumorigenesis of K-ras mutation in human endometrial carcinoma via upregulation of estrogen receptor. Gynecol Oncol 2006;101:274-9.
5. Uegaki K, Kanamori Y, Kigawa J, Kawaguchi W, Kaneko R, Naniwa J, Takahashi M, Shimada M, Oishi T, Itamochi H, Terakawa N. PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma. Oncol Rep 2005;14:389-92.
6. Pappa KI, Choleza M, Markaki S, Giannikaki E, Kyroudi A, Vlachos G, Voulgaris Z, Anagnou NP. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. Gynecol Oncol 2006;100:596-600.
7. Feng YZ, Shiozawa T, Miyamoto T, Kashima H, Kurai M, Suzuki A, Konishi I. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression. Clin Cancer Res 2005;11:6133-8.
8. Helmle KE, Otto CJ, Constantinescu G, Honore LH, Andrew SE. Variable MLH1 promoter methylation patterns in endometrial carcinomas of endometrioid subtype lacking DNA mismatch repair. Int J Gynecol Cancer 2005;15:1089-96.
9. Marias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Munoz J, Arguelles R, Machin P, Prat J. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001;32:569-77.
10. Griffin TJ, Gygi SP, Ideker T, Rist B, Eng J, Hood L, Aebersold R. Complementary profiling of gene expression at the transcriptome and proteome levels in Saccharomyces cerevisiae. Mol Cell Proteomics 2002;1:323-33.
11. Li ZY, Zhao X, Bai SJ, Wang Z, Chen LJ, Wei YQ, Huang CH. Proteomic identification of cyclophilin A as a potential prognostic factor and therapeutic target in endometrial carcinoma. Mol Cell Proteomics 10.1074/mcp.M700544- MCP200.
12. Fiumicino S, Ercoli A, Ferrandina G, Hess P, Raspaglio G, Genuardi M, Rovella V, Bellacosa A, Cicchillitti L, Mancuso S, Bignami M, Scambia G. Microsatellite instability is an independent indicator of recurrence in sporadic stage I-II endometrial adenocarcinoma. J Clin Oncol 2001;19:1008-14.
13. Maxwell GL, Risinger JI, Alvarez AA, Barrett JC, Berchuck A. Favorable survival associated with microsatellite instability in endometrioid endometrial cancers. Obstet Gynecol 2001;97:417-22.
14. Shih MC, Yeh KT, Tang KP, Chen JC, Chang JG. Promoter methylation in circadian genes of endometrial cancers detected by methylation-specific PCR. Mol Carcinog 2006;45:732-40.
15. MacDonald ND, Salvesen HB, Ryan A, Ivensen OE, Akslen LA, Jacobs IJ. Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas. Cancer Res 2000;60:1750-2.
16. Hohoff C, Borchers T, Rustow B, Spener F, van Tilbeurgh H. Expression, purification and crystal structure determination of recombinant human epidermal type fatty acid binding protein. Biochemistry 1999;38:12229-39.
17. Das R, Hammamieh R, Neill R, Melhem M, Jett M. Expression pattern of fatty acid-binding proteins in human normal and caner prostate cells and tissues. Clin Cancer Res 2001;7:1706-15.
18. Mooq-Lutz C, Bouillet P, Regnier CH, Tomasetto C, Mattei MG, Chenard MP, Anglard P, Rio MC, Basset P. Comparative expression of the psoriasin (S100A7) and S100C genes in breast carcinoma and co-localization to human chromosome 1q21-q22. Int J Cancer 1995;63:297-303.
19. Ji J, Zhao L, Wang X, Zhou C, Ding E, Su L, Zhang C, Mao X, Wu M, Liu Z. Differential expression of S100 gene family in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2004;130:480-6.
20. Ostergaard M, Rasmussen HH, Nielsen HV, Vorum H, Orntoft TF, Wolf H, Celis JE. Proteome profiling of bladder squamous cell carcinomas: identification of markers that define their degree of differentiation. Cancer Res 1997;57:4111-17.
21. Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN, Golub TR. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci USA 2000;97:3260-5.
22. Munz M, Zeidler R, Gires O. The tumour-associated antigen EpCAM upregulates the fatty acid binding protein E-FABP. Cancer Lett 2005;225:151-7.
23. Lecocq R, Lamy F, Erneux C, Dumont JE. Rapid purification and identification of calcyphosine, a Ca21-binding protein phosphorylated by protein kinase A. Biochem J 1995;306:147-51.
24. Clement S, Dumont JE, Schurmans S. Loss of calcyphosine gene expression in mouse and other rodents. Biochem Biophys Res Commun 1997;232:407-13.
25. Oyama Y, Shishibori T, Yamashita K, Naya T, Nakagiri S, Maeta H, Kobayashi R. Two distant anti-allergic drugs, amlexanox and cromolyn, bind to the same kinds of calcium binding proteins, except calmodulin, in bovine lung extract. Biochem Biophys Res Commun 1997;240:341-7.
26. de Bont JM, den Boer ML, Kros JM, Passier MM, Reddingius RE, Smitt PA, Luider TM, Pieters R. Identification of novel biomarkers in pediatric primitive neuroectodermal tumors and ependymomas by proteome-wide analysis. J Neuropathol Exp Neurol 2007;66:505-16.